GlassScriptPhysician profile
Apryl Watson
NPI 1447592472
$2,746.78
in general payments reported to CMS, 2019-2025
9 companies · $523 in 2025
The $523 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $290 · 2023: $916 · 2024: $1,018 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.42 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $934.57 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $459.10 | 2022-2025 | Dyanavel Xr |
| Corium, LLC | $409.90 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $336.08 | 2022-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $190.36 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $186.21 | 2024-2025 | Xelstrym, Secuado |
| Neos Therapeutics, LP | $126.04 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Idorsia Pharmaceuticals US INC | $73.21 | 2023-2025 | Quviviq, Quviviq |
| Dexcom, INC. | $31.31 | 2022-2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apryl Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.